Effects of atorvastatin and pravastatin on immune activation and T-cell function in antiretroviral therapy-suppressed HIV-1-infected patients

AIDS

Volumn 28, Issue 17, 2014, Pages 2627-2631

  Overton, Edgar Turner ^a   Sterrett, Sarah ^a   Westfall, Andrew O ^a   Kahan, Shannon M ^b   Burkholder, Greer ^a   Zajac, Allan J ^b   Goepfert, Paul A ^a,b   Bansal, Anju ^a  

^a UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

^b University of Alabama at Birmingham   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ATORVASTATIN; GAMMA INTERFERON; HLA DR ANTIGEN; PRAVASTATIN; ROSUVASTATIN; ANTIRETROVIRUS AGENT; HEPTANOIC ACID DERIVATIVE; HYPOCHOLESTEROLEMIC AGENT; IMMUNOLOGIC FACTOR; PYRROLE DERIVATIVE;

ANTIVIRAL THERAPY; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFECT; EX VIVO STUDY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; IN VITRO STUDY; LYMPHOCYTE FUNCTION; MEMORY T LYMPHOCYTE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION; DRUG EFFECTS; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; SECRETION (PROCESS); VIROLOGY;

ANTI-RETROVIRAL AGENTS; ANTICHOLESTEREMIC AGENTS; ATORVASTATIN CALCIUM; HEPTANOIC ACIDS; HIV INFECTIONS; HIV-1; HUMANS; IMMUNOLOGIC FACTORS; INTERFERON-GAMMA; LYMPHOCYTE ACTIVATION; PRAVASTATIN; PYRROLES; RETROSPECTIVE STUDIES; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES;

EID: 84927709788     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0000000000000475     Document Type: Article

References (33)

1. Ascher AMS. Sheppard HW. AIDS as immune system activation: a model for pathogenesis. Clin Exp Immunol 1988; 73: 165-167.
2. Giorgi JV. Hultin LE. McKeating JA. Johnson TD. Owens B. Jacobson LP. et al. Shorter survival in advanced human immunodeficiency virus type 1 infection is more closely associated with T lymphocyte activation than with plasma virus burden or virus chemokine coreceptor usage. J Infect Dis 1999; 179: 859-870.
3. Plaeger SF. Collins BS. Musib R. Deeks SG. Read S. Embry A. Immune activation in the pathogenesis of treated chronic HIV disease: a workshop summary. AIDS Res Hum Retroviruses 2012; 28: 469-477.
4. Sousa AE. Carneiro J. Meier-Schellersheim M. Grossman Z. Victorino RM. CD4 T cell depletion is linked directly to immune activation in the pathogenesis of HIV-1 and HIV-2 but only indirectly to the viral load. J Immunol 2002; 169: 3400-3406.
5. Hearps AC. Maisa A. Cheng WJ. Angelovich TA. Lichtfuss GF. Palmer CS. et al. HIV infection induces age-related changes to monocytes and innate immune activation in young men that persist despite combination antiretroviral therapy. AIDS 2012; 26: 843-853.
6. Jiang W. Lederman MM. Hunt P. Sieg SF. Haley K. Rodriguez B. et al. Plasma levels of bacterial DNA correlate with immune activation and the magnitude of immune restoration in persons with antiretroviral-treated HIV infection. J Infect Dis 2009; 199: 1177-1185.
7. Lederman MM. Calabrese L. Funderburg NT. Clagett B. Medvik K. Bonilla H. et al. Immunologic failure despite suppressive antiretroviral therapy is related to activation and turnover of memory CD4 cells. J Infect Dis 2011; 204: 1217-1226.
8. Burdo TH Lo J. Abbara S. Wei J. DeLelys ME. Preffer F. et al. Soluble CD163. a novel marker of activated macrophages. is elevated and associated with noncalcified coronary plaque in HIV-infected patients. J Infect Dis 2011; 204: 1227-1236.
9. Ledwaba L. Tavel JA. Khabo P. Maja P. Qin J. Sangweni P. et al. Pre-ART levels of inflammation and coagulation markers are strong predictors of death in a South African cohort with advanced HIV disease. PLoS One 2012; 7: e24243.
10. Sandler NG. Wand H. Roque A. Law M. Nason MC. Nixon DE. et al. Plasma levels of soluble CD14 independently predict mortality in HIV infection. J Infect Dis 2011; 203: 780-790.
11. French MA. King MS. Tschampa JM. da Silva BA. Landay AL. Serum immune activation markers are persistently increased in patients with HIV infection after 6 years of antiretroviral therapy despite suppression of viral replication and reconstitution of CD4R T cells. J Infect Dis 2009; 200: 1212-1215.
12. Gandhi RT. Spritzler J. Chan E. Asmuth DM. Rodriguez B. Merigan TC. et al. Effect of baseline-and treatment-related factors on immunologic recovery after initiation of antiretroviral therapy in HIV-1-positive subjects: results from ACTG 384. J Acquir Immune Defic Syndr 2006; 42: 426-434.
13. Hunt PW. Martin JN. Sinclair E. Bredt B. Hagos E. Lampiris H. et al. T cell activation is associated with lower CD4R T cell gains in human immunodeficiency virus-infected patients with sustained viral suppression during antiretroviral therapy. J Infect Dis 2003; 187: 1534-1543.
14. Robbins GK. Spritzler JG. Chan ES. Asmuth DM. Gandhi RT. Rodriguez BA. et al. Incomplete reconstitution of T cell subsets on combination antiretroviral therapy in the AIDS Clinical Trials Group protocol 384. Clin Infect Dis 2009; 48: 350-361.
15. Valdez H. Connick E. Smith KY. Lederman MM. Bosch RJ. Kim RS. et al. Limited immune restoration after 3 years' suppression of HIV-1 replication in patients with moderately advanced disease. AIDS 2002; 16: 1859-1866.
16. Expert Panel on Detection E. Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection. Evaluation. And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-2497.
17. Stone NJ. Robinson J. Lichtenstein AH. Merz CN. Blum CB. Eckel RH. et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014; 129: S1-S45.
18. Chung HK. Lee IK. Kang H. Suh JM. Kim H. Park KC. et al. Statin inhibits interferon-gamma-induced expression of intercellular adhesion molecule-1 (ICAM-1) in vascular endothelial and smooth muscle cells. Exp Mol Med 2002; 34: 451-461.
19. Li D. Chen H. Romeo F. Sawamura T. Saldeen T. Mehta JL. Statins modulate oxidized low-density lipoprotein-mediated adhesion molecule expression in human coronary artery endothelial cells: role of LOX-1. J Pharmacol Exp Ther 2002; 302: 601-605.
20. Omi H. Okayama N. Shimizu M. Fukutomi T. Imaeda K. Okouchi M. et al. Statins inhibit high glucose-mediated neutrophil-endothelial cell adhesion through decreasing surface expression of endothelial adhesion molecules by stimulating production of endothelial nitric oxide. Microvasc Res 2003; 65: 118-124.
21. Greenwood J. Mason JC. Statins and the vascular endothelial inflammatory response. Trends Immunol 2007; 28: 88-98.
22. Chao C. Xu L. Abrams DI. Towner WJ. Horberg MA. Leyden WA. et al. HMG-CoA reductase inhibitors (statins) use and risk of non-Hodgkin lymphoma in HIV-positive persons. AIDS 2011; 25: 1771-1777.
23. Moore RD. Bartlett JG. Gallant JE. Association between use of HMG CoA reductase inhibitors and mortality in HIV-infected patients. PLoS One 2011; 6: e21843.
24. Overton ET. Kitch D. Benson CA. Hunt PW. Stein JH. Smurzynski M. et al. Effect of statin therapy in reducing the risk of serious non-AIDS-defining events and nonaccidental death. Clin Infect Dis 2013; 56: 1471-1479.
25. Ganesan A. Crum-Cianflone N. Higgins J. Qin J. Rehm C. Metcalf J. et al. High dose atorvastatin decreases cellular markers of immune activation without affecting HIV-1 RNA levels: results of a double-blind randomized placebo controlled clinical trial. J Infect Dis 2011; 203: 756-764.
26. Kitahata MM. Rodriguez B. Haubrich R. Boswell S. Mathews WC. Lederman MM. et al. Cohort profile: the Centers for AIDS Research Network of Integrated Clinical Systems. Int J Epidemiol 2008; 37: 948-955.
27. Bansal A. Jackson B. West K. Wang S. Lu S. Kennedy JS. et al. Multifunctional T-cell characteristics induced by a polyvalent DNA prime/protein boost human immunodeficiency virus type 1 vaccine regimen given to healthy adults are dependent on the route and dose of administration. J Virol 2008; 82: 6458-6469.
28. Riou C. Treurnicht F. Abrahams MR. Mlisana K. Liu MK. Goonetilleke N. et al. Increased memory differentiation is associated with decreased polyfunctionality for HIV but not for cytomegalovirus-specific CD8R T cells. J Immunol 2012; 189: 3838-3847.
29. Desai S. Landay A. Early immune senescence in HIV disease. Curr HIV/AIDS Rep 2010; 7: 4-10.
30. Fuller MJ. Khanolkar A. Tebo AE. Zajac AJ. Maintenance. loss. and resurgence of T cell responses during acute. protracted. and chronic viral infections. J Immunol 2004; 172: 4204-4214.
31. Breton G. Chomont N. Takata H. Fromentin R. Ahlers J. Filali-Mouhim A. et al. Programmed death-1 is a marker for abnormal distribution of naive/memory T cell subsets in HIV-1 infection. J Immunol 2013; 191: 2194-2204.
32. Velu V. Titanji K. Zhu B. Husain S. Pladevega A. Lai L. et al. Enhancing SIV-specific immunity in vivo by PD-1 blockade. Nature 2009; 458: 206-210.
33. Sakhdari A. Mujib S. Vali B. Yue FY. MacParland S. Clayton K. et al. Tim-3 negatively regulates cytotoxicity in exhausted CD8R T cells in HIV infection. PLoS One 2012; 7: e40146.